About OceanView
Why we built this publication, what makes it different, and how we work.
Why OceanView Exists
In 2021, after a decade of reading analyst reports on Israeli tech companies — the kind investment banks crank out, the kind that always seem to have a "buy" rating attached — I noticed a pattern. The reports were beautifully formatted. The logos were crisp. But when you cross-referenced the claims against actual SEC filings, the picture didn't always match.
Not because anyone was lying. Because sell-side research has structural incentives that tilt toward optimism. And most tech journalism, frankly, doesn't have the time or the specialized knowledge to dig through a 200-page 10-K filing before deadline.
So OceanView started as a personal project: take the same public documents anyone can download from EDGAR, read them carefully, and write up what they actually say. No ratings. No price targets. No investment recommendations of any kind. Just an honest attempt to understand what these companies do, how they make money, and where they fit in their respective industries.
Over time it grew into a publication with a small but engaged readership — mostly people working in the Israeli tech ecosystem who want depth without the sales pitch. We now cover roughly 120 publicly-listed Israeli tech firms across cybersecurity, agritech, and medical devices.
What We Do
- Analyze public filings. 10-K annual reports, 10-Q quarterly updates, S-1 IPO prospectuses, and 8-K material event filings from the SEC EDGAR system. For dual-listed Israeli companies, we also review TASE submissions.
- Summarize earnings calls. We listen to quarterly earnings calls — both the prepared remarks and the Q&A — and highlight discrepancies between what management says and what the numbers show.
- Map competitive landscapes. For each sector we cover, we maintain an ongoing map of who competes with whom, based on public disclosures, industry reports, and product comparisons.
- Explain regulatory context. FDA approval timelines for medical devices, cybersecurity certification frameworks, agriculture technology patents — the boring but essential context that determines whether a product actually reaches market.
What We Don't Do
- Investment advice. We do not recommend stocks, make price predictions, or tell anyone what to buy or sell. Period. Our content is descriptive, not prescriptive.
- Sponsored content without disclosure. We don't currently accept sponsored content at all. If that changes, any sponsored material will be labeled at the top of the article.
- Rumor-based reporting. If it doesn't appear in a public filing, an earnings call, or a reputable industry source, we don't publish it.
- Company-paid research. We are not compensated by companies we cover. We do not hold positions in any stock we analyze.
Methodology: How We Do Research
Every article on OceanView follows a consistent research process. We document this not because it makes us sound authoritative, but so readers can evaluate our methods and decide for themselves whether our analysis is credible.
Primary sources come first. For any company we analyze, we start with the most recent SEC filing — typically the 10-K or 20-F for annual data, supplemented by 10-Q quarterly reports. These are the legally-binding documents where companies disclose revenue, costs, risk factors, related-party transactions, and management discussion. We download them from the SEC EDGAR database.
Earnings calls are reviewed in full. We listen to or read the transcript of each quarterly earnings call, paying particular attention to the Q&A portion — this is where analysts press management on weak points. We compare forward-looking statements against subsequent reported results.
Industry context comes from independent sources. For market size estimates, we use reports from research firms like Gartner, IDC, and Frost & Sullivan — always cited with a link where available. For regulatory details, we reference primary sources: FDA databases, patent office records, and Israeli Innovation Authority publications.
Every factual claim is sourced. Within each article, we link directly to the documents we reference. At the bottom of every article, you'll find a "References" section with URLs to the original sources. If something can't be sourced, we note that explicitly.
Corrections policy. If we discover an error or a reader points one out, we correct it and add a dated correction note at the top of the article. We don't silently edit mistakes.
Review before publication. Each article is written by John Johnson, reviewed for factual accuracy against source documents, and published with a clear date. Articles are periodically updated when new filings or developments warrant — and the "last updated" date reflects those revisions.
This process is not perfect. SEC filings contain errors. Earnings calls involve selective disclosure. Our interpretation might miss something. But we'd rather be transparent about our process than pretend to have perfect insight.
About the Author
John Johnson is a Tel Aviv-based technology analyst with over 12 years of experience tracking Israeli public technology companies. His work centers on SEC filings analysis, earnings call transcript review, and competitive landscape mapping across cybersecurity, agritech, and medical device sectors.
He holds a Bachelor's degree in Economics and has spent his career working with financial data and corporate strategy — though he prefers to describe his job as "reading footnotes so you don't have to." John has lived in Israel since 2010 and works from Bnei Brak.
You can reach him at johnjohnson409@mail.com.
Operating Entity
OceanView is operated by OceanView Ltd., registered at Jabotinsky Street 830, Bnei Brak 6645675, Israel. This page was last updated on March 15, 2025.